drugset
drugset / Trial / NCT00749879

Crossover Study of the Safety and PK Properties of Proellex®

NCT00749879 ↗

Phase 1 Completed 17 enrolled Repros Therapeutics Inc.
RandomizedCrossoverOpen-labelBasic science

Summary

Study to evaluate the PK of 25 mg and 50 mg of Proellex from 2 different suppliers in the fed and fasting states.

Timeline

Start
2008-08-11
Primary completion
2008-10-23
Completion
2008-10-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Telapristone Acetate Other / unclassified 25 mg Oral
Subject Telapristone Acetate Other / unclassified 50 mg Oral

Indications

No indication recorded.